Lyo-X
Lyo-X is recorded as a service provider in 5 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 5 of 5 trials · Latest update first
A multicenter, first-in-human, dose escalation and optimization phase I/IIa study to investigate safety, tolerability, pharmacokinetics, and efficacy of the NaPi2b antibody-drug conjugate TUB-040 in patients with platinum-resistant high-grade ovarian cancer (PROC) or relapsed/refractory adenocarcinoma non-small cell lung cancer (NSCLC) (NAPISTAR 1-01).
Sponsor Gilead Sciences Inc.
- Start (EU)
- Latest update
- Estimated end
A Multicenter First-in-human Dose Escalation and Optimization Phase I/IIa Trial to Investigate Safety, Tolerability, Pharmacokinetics, and Efficacy of the 5T4 Antibody-Drug Conjugate TUB-030 in Patients with Advanced Solid Tumors (5-STAR 1-01)
Sponsor Gilead Sciences Inc.
- Start (EU)
- Latest update
- Estimated end
A first-in-human (FIH) clinical trial to investigate the human monoclonal antibody NG004, administrated intrathecally in acute spinal cord injury (SCI) patients
Sponsor NovaGo Therapeutics AG
- Start (EU)
- Latest update
- Estimated end
A multicenter, Phase Ib/II study to evaluate the safety, tolerability, pharmacokinetics and preliminary clinical activity of TUB-040, in combination with standard ovarian cancer drugs in patients with high-grade epithelial serous or endometrioid epithelial ovarian cancer (OC) (NAPISTAR 1-02)
Sponsor Gilead Sciences Inc.
- Start (EU)
- Latest update
- Estimated end
A randomized, single-blind trial to evaluate the safety and efficacy of apraglutide in subjects with Grade II to IV (MAGIC) steroid refractory gastrointestinal (GI) acute graft versus host disease on best available therapy.
Sponsor VectivBio AG
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Lyo-X?
The 2026-10-09 snapshot links Lyo-X to 5 distinct CTIS trials. Recorded services include Statistical analysis, Laboratory services. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Lyo-X?
The most frequently recorded therapeutic areas are Solid Tumor Oncology, Gynecology, Neurology, Respiratory. Recorded phases include Phase 1, Phase 2. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Lyo-X conducted?
The linked trials record locations in 6 countries, including Germany, Belgium, Spain, Romania, Switzerland. These are trial locations, not confirmed office locations or countries where Lyo-X delivered services.
What can this page tell me about Lyo-X's trial experience?
Browse 5 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Lyo-X. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Lyo-X AG